Geena Davis to star in HBO Dorothea Puente drama
Oscar winner Geena Davis will star in and executive produce *Dorothea*, an HBO drama about serial killer Dorothea Puente, who murdered at least nine elderly and disabled tenants in the 1980s. Davis's
Oscar winner Geena Davis will star in *Dorothea*, an HBO true-crime drama about California’s most notorious female serial killer, Dorothea Puente. Dav
Read Full Story at Deadline Hollywood →Why This Matters
Geena Davis's involvement in *Dorothea* signals a shift toward nuanced portrayals of female villains in prestige television, challenging the industry's historical reluctance to explore complex female antagonists beyond tropes. The project also underscores HBO's ongoing commitment to true crime dramas with feminist perspectives, a niche that has gained traction amid debates about media exploitation of real-life tragedies.
Background Context
Dorothea Puente's 1980s Sacramento boarding house murders exposed systemic failures in elderly care and social services, revealing how vulnerable populations were exploited by predatory systems. The case coincided with a national reckoning over institutional neglect, yet Puente's crimes were often sensationalized over the policy failures that enabled them, a dynamic that persists in true crime narratives today.
What Happens Next
The adaptation's success could accelerate more high-profile true crime dramas centered on female perpetrators, pushing networks to prioritize psychological depth over shock value. Questions linger about how Davis and the creative team will navigate the ethical tightrope of dramatizing real suffering while avoiding exploitative tropes that have marred similar projects.
Bigger Picture
The rise of female-led true crime stories reflects broader cultural shifts in how society consumes and critiques narratives about women who commit violence, moving beyond simplistic victim/perpetrator binaries. This trend also intersects with the growing demand for content that interrogates systemic failures rather than glorifying individual pathologies.
